INS and type 2 diabetes mellitus: The second Phase II study compared BIF with degludec in 278 insulin-naive participants with type 2 diabetes being treated with metformin with or without a DPP4i and/or sodium–glucose cotransporter 2 inhibitor (SGLT2i), with a fasting glucose target of 4.4–5.6 mmol/l [27].